Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IIITerminatedD-0001-2018

Drug recall · October 11, 2017

Deferoxamine Mesylate for injection recall

Why: CGMP Deviations: Firm failed to control impurity for color change at the API stage.

Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).

The recall

Product

Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10.

Lots / codes

Lot: 51275DD; Exp. 09/01/17

Quantity
32,276 10 mL vials
Company
Pfizer Inc., New York, NY
Distribution
Nationwide
Initiated
July 12, 2017 · Voluntary: Firm initiated
Classified
October 3, 2017
Reported
October 11, 2017
Ended
July 16, 2020
How notified
Letter

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.